Last reviewed · How we verify
Polygynax combinaison of polymyxin, Neomycin and Nystatin
Polygynax combinaison of polymyxin, Neomycin and Nystatin is a Small molecule drug developed by Laboratoire Innotech International. It is currently FDA-approved.
At a glance
| Generic name | Polygynax combinaison of polymyxin, Neomycin and Nystatin |
|---|---|
| Sponsor | Laboratoire Innotech International |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polygynax combinaison of polymyxin, Neomycin and Nystatin CI brief — competitive landscape report
- Polygynax combinaison of polymyxin, Neomycin and Nystatin updates RSS · CI watch RSS
- Laboratoire Innotech International portfolio CI
Frequently asked questions about Polygynax combinaison of polymyxin, Neomycin and Nystatin
What is Polygynax combinaison of polymyxin, Neomycin and Nystatin?
Polygynax combinaison of polymyxin, Neomycin and Nystatin is a Small molecule drug developed by Laboratoire Innotech International.
Who makes Polygynax combinaison of polymyxin, Neomycin and Nystatin?
Polygynax combinaison of polymyxin, Neomycin and Nystatin is developed and marketed by Laboratoire Innotech International (see full Laboratoire Innotech International pipeline at /company/laboratoire-innotech-international).
What development phase is Polygynax combinaison of polymyxin, Neomycin and Nystatin in?
Polygynax combinaison of polymyxin, Neomycin and Nystatin is FDA-approved (marketed).